{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-209920","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2024-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.640539+00:00","generated_at":"2026-05-31T07:01:39.605252+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Artiva reports Q2 net loss $17.8M; IPO raises $179M extending cash runway through 2026","bullets":["IPO in July 2024 raised $179M gross; cash $46.6M pre-IPO, runway now through 2026.","Net loss Q2 2024: $17.8M vs $11.3M YoY; R&D expense $12.3M (up 9%).","Collaboration revenue $0 vs $3.5M in Q2 2023 after Merck deal termination.","First patient dosed in autoimmune basket trial (AlloNK + rituximab); first LN patient in Phase 1/1b.","Expect initial AlloNK autoimmune data in H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-209920","json":"https://secwatch.observer/filing/0001193125-24-209920.json","markdown":"https://secwatch.observer/filing/0001193125-24-209920.md","text":"https://secwatch.observer/filing/0001193125-24-209920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312524209920/0001193125-24-209920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312524209920/d890088d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:01:39.605252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}